Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04319601
Other study ID # RLC
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 13, 2020
Est. completion date December 31, 2022

Study information

Verified date March 2020
Source Zhejiang Cancer Hospital
Contact Cong Li, MD
Phone +8615267115611
Email licong@zjcc.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to explore the effeicency and toxicities of rituximab combined with chidamide and lenalidomide in patients with relapsed or refractory AITL.


Description:

This study is designed to explore the effeicency and toxicities of rituximab combined with chidamide and lenalidomide in patients with relapsed or refractory AITL. The primary end point is PFS, and second end point is OS, ORR and toxicities according to CTCAE 5.0.


Recruitment information / eligibility

Status Recruiting
Enrollment 26
Est. completion date December 31, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Subjects must voluntarily participate in this study and sign an informed consent. 2. 18-70 years old. 3. ECOG 0-2. 4. Life expectancy =12 weeks. 5. Histopathology diagnosis of AITL. 6. A measurable lesion (lymphoma nodule, lymph node mass or other lymphoma lesions as defined in lugano 2014) that can be measured in both diameters on the CT scan, including the longest diameter and the shortest diameter perpendicular to the longest diameter.In addition, the longest diameter of lymph nodes should be greater than 1.5cm, and the longest diameter of external lymph node lesions should be greater than 1.0cm. 7. The patient has received at least one line of systemic chemotherapy and currently has disease progression or treatment failure, or the patient refuses or cannot tolerate intravenous chemotherapy. 8. Adequate bone marrow hematopoietic function reserve and viscera function, as follows: Liver function: ALT, AST=2.5 times the normal upper limit, if there is liver metastasis, =5 times the normal upper limit;Total bilirubin, direct bilirubin =1.5 times the normal upper limit. Bone marrow function (growth factor should not be used within 7 days before the first medication) : WBC =2.0*109/l;The ANC acuity 1.0 * 109 / l;PLT 50 * 109 / l or higher;Hb 8 g/dl or higher. Renal function: creatinine =1.5 times the normal upper limit or creatinine clearance =30ml/min. Cardiac function: LVEF=50%. Lung function: resting and oxygen saturation =95% without oxygen inhalation. Coagulation function: international standardized ratio (INR) =1.5×ULN and activated partial thromboplastin time (aPTT) =1.5×ULN, unless the patient is receiving anticoagulation therapy and the coagulation parameters (prothrombin time [PT/INR] and aPTT) at the time of screening are within the expected range of anticoagulant treatment.Patients whose prolongation of PT or elevation of INR resulted from the use of clotting factor inhibitors were eligible for inclusion by the investigator. Exclusion Criteria: 1. Prior to the first use of the drug in this study, there was an unrelieved drug toxicity greater than CTCAE1 (except for the adverse reactions, such as hair loss, that the investigator assessed did not affect the use of the drug in this study). 2. Presence of active infection, including but not limited to: known active/latent tuberculosis, herpes zoster, pneumonia. 3, Known human immunodeficiency virus (HIV) infection, or reflect the activity of hepatitis b virus (HBV) or hepatitis c virus (HCV) infection of serological status: a. the hepatitis b surface antigen (HBsAg) positive, HBcAb positive, HBsAg positive patients should be detected HBV - DNA, if not more than 1000 iu/ml and agreed to accept patients treated against HBV virus can enter the group.B. patients with positive HCV antibody are admitted if HCV RNA (<15 IU/mL) is not detected. 4. Patients with heart failure of grade 3 or 4 according to the New York society of cardiology (NYHA) functional classification, unstable angina, severe poorly controlled ventricular arrhythmia, electrocardiogram showing acute ischemia or myocardial infarction 6 months prior to screening.Or other cardiac dysfunction assessed by the investigator as not resistant to chemotherapy. 5. Support the treatment of refractory nausea, vomiting, chronic gastrointestinal diseases, capsule dysphagia, or previous surgical resection of the intestinal segment may affect the full absorption of drugs. 6. The investigator's judgment or other evidence indicates that the patient has serious or poorly controlled systemic diseases, including poorly controlled hypertension and an active bleeding constitution.At present, patients with thrombotic diseases such as pulmonary embolism and deep vein thrombosis are also not suitable to participate in this study. 7. Nursing or pregnant women. 8. The researcher judged that the patient had other factors that might affect the compliance of the plan.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rituximab
a new chemotherapy regimen

Locations

Country Name City State
China Zhejiang Cancer Hospital Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary PFS progression free survival From enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 32 months
Secondary ORR overall response rate From enrollment until date of completion of chemotherapy, assessed up to 9 months
Secondary toxicities Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 from enrollment to 30 days after completion of chemotherapy, assessed up to 9 months
See also
  Status Clinical Trial Phase
Recruiting NCT06376604 - Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies N/A
Completed NCT03753542 - Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy N/A
Not yet recruiting NCT05022628 - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis Phase 4
Completed NCT04207359 - Effects of Creatine Supplementation in Breast Cancer Survivors N/A
Active, not recruiting NCT04489173 - TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer Phase 2
Completed NCT04173195 - Comfort Talk (CT) During Outpatient Chemotherapy N/A
Recruiting NCT06041477 - Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC Phase 3
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Recruiting NCT03275194 - HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy Phase 2
Recruiting NCT04808466 - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT06421610 - OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. Phase 1
Completed NCT05131490 - Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients N/A
Completed NCT04118322 - The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy N/A
Recruiting NCT06043999 - Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients N/A
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Not yet recruiting NCT04845490 - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT05992337 - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Recruiting NCT05424692 - Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer N/A
Recruiting NCT04989985 - S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma Phase 2
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A